Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein
about
Regulation of glucose homeostasis by GLP-1Mechanisms of action of glucagon-like peptide 1 in the pancreasNew insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-cateninThe effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant modelGlutathione- and thioredoxin-related enzymes are modulated by sulfur-containing chemopreventive agentsAMP-activated protein kinase (AMPK) mediates nutrient regulation of thioredoxin-interacting protein (TXNIP) in pancreatic beta-cellsPreclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor AgonistsMinireview: Thioredoxin-interacting protein: regulation and function in the pancreatic β-cell.Exendin-4 protects mitochondria from reactive oxygen species induced apoptosis in pancreatic Beta cells.GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) miceProteomic analysis of INS-1 rat insulinoma cells: ER stress effects and the protective role of exenatide, a GLP-1 receptor agonistThioredoxin binding protein (TBP)-2/Txnip and α-arrestin proteins in cancer and diabetes mellitus.A noncytolytic antibody-like extendin-4-IgG4 fusion protein as a long-acting potential anti-diabetic agent.The role of the Wnt signaling pathway in incretin hormone production and function.Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance.Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis.Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting proteinTargeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies.A review of exenatide as adjunctive therapy in patients with type 2 diabetes.The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.Physiological insights gained from gene expression analysis in obesity and diabetes.Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.Suppressors of cytokine signaling (SOCS) and type 2 diabetes.Thioredoxin-interacting protein: pathophysiology and emerging pharmacotherapeutics in cardiovascular disease and diabetes.Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.High beta-cell mass prevents streptozotocin-induced diabetes in thioredoxin-interacting protein-deficient mice.Incretin effects on β-cell function, replication, and mass: the human perspective.Exenatide pretreatment improved graft function in nonhuman primate islet recipients compared to treatment after transplant only.Expanding treatment options for type 2 diabetes: the old and the new.Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes.Exendin-4 treatment expands graft beta-cell mass in diabetic mice transplanted with a marginal number of fresh islets.Mir-204 Controls Glucagon-Like Peptide 1 Receptor Expression and Agonist Function.Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: potential antioxidant effects.W2476 ameliorates β-cell dysfunction and exerts therapeutic effects in mouse models of diabetes via modulation of the thioredoxin-interacting protein signaling pathway.Geniposide accelerates proteasome degradation of Txnip to inhibit insulin secretion in pancreatic β-cells.Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP.
P2860
Q24563430-17CE705C-D221-4B1E-8E81-AE369EA935FFQ24683764-83D01B70-4F86-49E2-B3CB-F240D080611DQ26823824-F35916E0-FC59-44E8-8A8D-98472D0E8754Q27311069-A80A099C-F01B-4A64-8D42-B14DE2FA2FAEQ28253359-3EF482FC-9AC7-472C-8FCB-65317148D5FDQ28741436-1A0B0D81-8EFD-44C0-AD79-2F1C67D00451Q33521451-11410123-7D93-4EEC-9481-BA5D199AFDC7Q33977405-A1B9FAC7-9DD7-4E5C-BCAD-26CF45914963Q35034582-723F7F37-5E58-485A-8F09-9134025445E0Q35059492-F896A718-91B7-4EF2-86D9-B771DD1B5F29Q35582227-F7AADF1F-7CDF-43BD-A836-778A8311E223Q35634417-2BDD9F07-F388-46EA-8149-08ABFD356B80Q35643633-2EF10BE1-40CA-4A68-8BDF-C53CAB825404Q36193707-E5668366-4B75-4467-8426-33C3FF762736Q36629722-6F5E1FF2-4A2D-4181-BF6E-294F7A5D3EB7Q36745735-0CF8C547-2983-4AE8-8E99-E4CACBCA00EEQ37190118-F6F78080-C063-4119-9102-4579057D1A2AQ37270524-AE939FA0-2554-4209-AA42-E17DD0E696A2Q37402790-AC9626FE-B529-4989-ACC9-D37444FE8538Q37403218-F95A7448-4609-43E5-A936-393EB6EC22F0Q37652799-07C1E5C7-C56C-4FC4-B9DE-5E90F11A5D9AQ37736477-1AD54E8D-E5ED-4885-82D5-4CBC44AFBD3DQ38095231-6D14A617-4775-413C-815C-13A1DC327811Q38177673-B1F5A2D1-CC3B-41DB-85C1-E2395B9A512CQ38236593-98E7CCE2-E37E-433D-AB08-87C95D110AC2Q38841043-7C858D50-725E-4295-AF3C-0C8AC1E7B326Q39882740-EEBB8A9A-A55B-4F27-8BF2-FA136E2A757DQ39988564-B385B0A8-0BD4-4BD5-B79C-6EDD4D1ED06BQ41846077-B92DE210-A1B8-4DC0-BF53-F26CA6078A0AQ46121472-CD2E58FE-8C50-47E2-8F52-3E4928D4FF0EQ46140543-842D6924-BDF9-45E8-A9BB-FC74BAA7E4FFQ46345362-6BD5F779-70CA-4BB6-830D-407B700CA7C1Q47443146-AF696201-32C0-430A-9E9C-E1A7BB072D62Q50057404-C08922EA-47E0-48B6-9D4C-507B8B82D78EQ51002471-FF94EEB9-F884-4942-958C-C4F3D9C364B0Q51246114-C8561290-1F0A-430C-BED0-F0E9C220B188Q52709221-96B4F495-5910-45FA-9B3C-03988832CC96
P2860
Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein
description
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im August 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2006/08/04)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd op 2006/08/04)
@nl
наукова стаття, опублікована в серпні 2006
@uk
مقالة علمية (نشرت في 4-8-2006)
@ar
name
Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein
@ast
Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein
@en
Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein
@nl
type
label
Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein
@ast
Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein
@en
Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein
@nl
prefLabel
Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein
@ast
Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein
@en
Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein
@nl
P2093
P1476
Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein
@en
P2093
Alexandra H. Minn
Anath Shalev
Francesca M. Couto
Junqin Chen
P304
P356
10.1016/J.BBRC.2006.06.027
P407
P577
2006-08-04T00:00:00Z